Jessica Kimmel1, Jordan Axelrad2. 1. Division of Gastroenterology, Department of Medicine, New York University School of Medicine, New York, NY, USA. kimmeljessica@gmail.com. 2. Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center at New York University Langone Health, New York University School of Medicine, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: Both the chronic inflammation in inflammatory bowel disease (IBD), and its treatment, can increase the risk of malignancy. There is also an increasing number of patients with current and prior cancer who require IBD treatment. Thus, there is a complex interplay between immunosuppressive treatment and monitoring for new and recurrent cancer. RECENT FINDINGS: Vedolizumab and ustekinumab have not been shown to increase the risk of malignancy. Transplant data shows a potential risk with tofacitinib although rheumatoid arthritis data does not. IBD patients have been shown to tolerate chemotherapy, specifically with cytotoxic compared with hormonal chemotherapy. Patients with prior cancer are at increased risk of new or recurrent cancers; however, immunosuppression appears to be safe. Emerging treatments for IBD have demonstrated acceptable safety profiles for malignancy risk, and immunosuppression appears to be safe for use in patients with current and prior malignancy. More data is still needed to assess long-term risk of malignancy in these patients, especially with newer treatments.
PURPOSE OF REVIEW: Both the chronic inflammation in inflammatory bowel disease (IBD), and its treatment, can increase the risk of malignancy. There is also an increasing number of patients with current and prior cancer who require IBD treatment. Thus, there is a complex interplay between immunosuppressive treatment and monitoring for new and recurrent cancer. RECENT FINDINGS:Vedolizumab and ustekinumab have not been shown to increase the risk of malignancy. Transplant data shows a potential risk with tofacitinib although rheumatoid arthritis data does not. IBDpatients have been shown to tolerate chemotherapy, specifically with cytotoxic compared with hormonal chemotherapy. Patients with prior cancer are at increased risk of new or recurrent cancers; however, immunosuppression appears to be safe. Emerging treatments for IBD have demonstrated acceptable safety profiles for malignancy risk, and immunosuppression appears to be safe for use in patients with current and prior malignancy. More data is still needed to assess long-term risk of malignancy in these patients, especially with newer treatments.
Authors: Waqqas Afif; William J Sandborn; William A Faubion; Meher Rahman; Scott W Harmsen; Alan R Zinsmeister; Edward V Loftus Journal: Inflamm Bowel Dis Date: 2013-06 Impact factor: 5.325
Authors: F Vincenti; H Tedesco Silva; S Busque; P O'Connell; J Friedewald; D Cibrik; K Budde; A Yoshida; S Cohney; W Weimar; Y S Kim; N Lawendy; S-P Lan; E Kudlacz; S Krishnaswami; G Chan Journal: Am J Transplant Date: 2012-06-08 Impact factor: 8.086
Authors: Laurent Beaugerie; Nicole Brousse; Anne Marie Bouvier; Jean Frédéric Colombel; Marc Lémann; Jacques Cosnes; Xavier Hébuterne; Antoine Cortot; Yoram Bouhnik; Jean Pierre Gendre; Tabassome Simon; Marc Maynadié; Olivier Hermine; Jean Faivre; Fabrice Carrat Journal: Lancet Date: 2009-11-07 Impact factor: 79.321
Authors: Tine Jess; Erzsébet Horváth-Puhó; Jan Fallingborg; Henrik H Rasmussen; Bent A Jacobsen Journal: Am J Gastroenterol Date: 2013-08-27 Impact factor: 10.864
Authors: Tiziana Larussa; Antonio Basile; Caterina Palleria; Chiara Iannelli; Ada Vero; Lidia Giubilei; Caterina De Sarro; Evelina Suraci; Raffaella Marasco; Maria Imeneo; Emilio Russo; Ludovico Abenavoli; Giovambattista De Sarro; Francesco Luzza Journal: Med Pharm Rep Date: 2021-07-29
Authors: Åsa H Everhov; Rune Erichsen; Jacob Järås; Lars Pedersen; Jonas Halfvarson; Johan Askling; Anders Ekbom; Jonas F Ludvigsson; Henrik Toft Sørensen; Ola Olén Journal: Aliment Pharmacol Ther Date: 2022-08-02 Impact factor: 9.524